Navigation Links
Hormone therapy increases invasive breast cancer and mortality, WHI 11-year follow up finds
Date:10/20/2010

BUFFALO, N.Y. -- Results of a new Women's Health Initiative (WHI) report show that hormone therapy is associated with an increased the risk of death from breast cancer, as well as an increased risk of developing invasive breast cancer in postmenopausal women.

Jean Wactawski-Wende, PhD, professor of social and preventive medicine at the University at Buffalo and one of the primary authors on the paper, published today in JAMA, says the breast cancers found in these women also tended to have more lymph node involvement, indicating a poorer prognosis.

"This report, which expands on earlier results of the WHI study, followed these women for an average of 11 years," says Wactawski-Wende. "The data show that, with further follow-up, there remains an increased incidence of breast cancer in women taking estrogen plus progestin.

"In fact, women taking estrogen plus progestin are more likely to die from breast cancer and from other causes than women who did not take these hormones."

The paper was posted online Oct. 19 at http://jama.ama-assn.org/cgi/reprint/304/15/1684.

Wactawski-Wende was co-PI at UB's WHI Vanguard Center, one of 16 that helped develop the initial protocols for the study, which began in 1993 and eventually included 40 clinical centers across the U.S. Initially planned to continue until 2005, the hormone trial was halted in 2002 because preliminary analysis of the data showed estrogen plus progestin increased the risk of heart disease, stroke and invasive breast cancer. Prior to WHI, scientists speculated that hormone therapy reduced heart disease risk.

The WHI continued to follow these women after the main trial ended. The current JAMA paper reports the results of research conducted during this WHI extension phase. Most of the earlier observational studies, which follow participants over time and collect health information at specific intervals, had suggested that breast cancers that develop in women taking hormone therapy were less advanced and had a lower risk of death.

However, the WHI researchers note in the JAMA paper that the influence of estrogen plus progestin on breast cancer mortality had not been addressed in the context of a randomized clinical trial, prior to WHI.

Their current study to answer that question was based on 12,788 surviving postmenopausal women who took part in the initial trial.

Results showed that combined hormone therapy increases the incidence of invasive breast cancer and that, more commonly, the cancers had spread to the lymph nodes. There also were more deaths attributed to breast cancer in those taking hormone therapy -- 2.6 versus 1.3 per 10,000 women. There also were more deaths from all causes in the women who had been diagnosed with breast cancer who were on hormone therapy -- 5.3 versus 3.4 per 10,000.

The trial also found that hormone therapy interfered with detection of breast cancer, leading to cancers being diagnosed at a more advanced stage.

"These findings related to increased mortality in estrogen plus progestin users were surprising," says Wactawski-Wende. "Prior studies had suggested that, although these women were diagnosed with breast cancer, their prognosis was more positive than those who were not on hormone therapy when diagnosed. This study emphasizes the importance of clinical trial data to understand the risks and benefits of taking hormone therapy."


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Related medicine news :

1. New findings further clarify breast cancer risk with hormone therapy
2. Breast cancer risk varies among different progestins used in hormone replacement therapy
3. Surgery better than radiation, hormone treatments for some prostate cancer, study shows
4. Oral contraceptives and hormone replacement therapy may protect women against brain aneurysms
5. Adiposity hormone, leptin, regulates food intake by influencing learning and memory
6. Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones
7. Upcoming Simulcast to Teach Women How to Lose Weight and Naturally Balance Hormones with Polycystic Ovarian Syndrome
8. Targeting flight-or-fight hormone response to combat heart failure
9. Hormone Raises Desire for Fattening Foods
10. Flame retardant linked to altered thyroid hormone levels during pregnancy
11. Women with Polycystic Ovarian Syndrome and Insulin Resistance can Lose Weight and Balance Hormones Naturally with Katie Humphrey's New E-book
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: